Episodios

  • 04_07 Localized Renal Cell Carcinoma
    Jul 6 2024

    1. Risk Factors and Presentation
    2. Staging and Paraneoplastic syndromes
    3. Localized Therapy Options and Considerations
    4. Evidence and Limitations for Adjuvant Systemic Therapy

    Citations

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.


    1. Tannock IF et al. Evaluating Trials of Adjuvant Therapy: Is There Benefit for People with Resected Renal Cancer? Journal of Clinical Oncology. 2023;41(15):2713-2717. doi:10.1200/JCO.23.00280/ASSET/IMAGES/LARGE/JCO.23.00280F2.JPEG

    2. Ravaud A et al. NEJM. 2016;375(23):2246-2254. doi:10.1056/NEJMOA1611406/

    3. Pal SK et al. Lancet. 2022;400(10358):1103-1116. doi:10.1016/S0140-6736(22)01658-0

    4. Motzer RJ et al. Lancet. 2023;401(10379):821-832. doi:10.1016/S0140-6736(22)02574-0

    5. Correa AF et al. Eur Urol. 2021;80(1):20-31. doi:10.1016/J.EURURO.2021.02.025

    6. Choueiri TK et al. NEJM. 2024;390(15):1359-1371. doi:10.1056/NEJMOA2312695/

    7. Choueiri TK et al. NEJM. 2021;385(8):683-694. doi:10.1056/NEJMOA2106391/

    Disclosures

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags

    Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    Más Menos
    25 m
  • 04_06 Metastatic Urothelial Cancer
    May 24 2024

    1. Immunohistochemistry of urothelial cancer
    2. History of systemic therapy in advanced and metastatic disease
    3. Pembrolizumab and Enfortumab Vedotin
    4. Approach to second line therapy and beyond

    Citations

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.

    1. Powles T et al. NEJM. 2024;390(10):875-888. doi:10.1056/NEJMOA2312117/

    2. Powles T et al. NEJM. 2020;383(13):1218-1230. doi:10.1056/NEJMOA2002788/

    3. Galsky MD et al. Lancet. 2020;395(10236):1547-1557. doi:10.1016/S0140-6736(20)30230-0

    4. Powles T et al. Lancet Oncol. 2021;22(7):931-945. doi:10.1016/S1470-2045(21)00152-2

    5. van der Heijden MS et al. NEJM. 2023;389(19):1778-1789. doi:10.1056/NEJMOA2309863/

    6. Von der Maase H et al. JCO. 2000;18(17):3068-3077. doi:10.1200/JCO.2000.18.17.3068/

    7. von der Maase H et al. JCO. 2023;41(23):3881-3890. doi:10.1200/JCO.22.02763

    8. Vuky J et al. . JCO. 2020;38(23):2658-2666. doi:10.1200/JCO.19.01213

    Disclosures

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags

    Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    Más Menos
    25 m
  • 04_05 Muscle Invasive Bladder Cancer
    Apr 20 2024

    1. Etymology, presentation, and work-up of bladder/urothelial cancer
    2. Role of perioperative systemic therapy
    3. Tri-modality therapy (bladder sparing approach)
    4. Considerations for upper tract urothelial cancer

    Citations

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.


    1. Bellmunt J et al. Lancet Oncol. 2021;22(4):525-537. doi:10.1016/S1470-2045(21)00004-8

    2. Birtle AJ et al. JCO. Published online February 13, 2024. doi:10.1200/JCO.23.01659

    3. Birtle A et al. Lancet. 2020;395(10232):1268-1277. doi:10.1016/S0140-6736(20)30415-3

    4. Bajorin DF et al. NEJM. 2021;384(22):2102-2114. doi:10.1056/NEJMOA2034442/

    5. James ND et al. NEJM. 2012;366(16):1477-1488. doi:10.1056/NEJMOA1106106/

    6. Pfister C et al. JCO 2023;41(17_suppl) doi:10.1200/JCO.2023.41.17_SUPPL.LBA4507

    7. Pfister C et al. Eur Urol. 2021;79(2):214-221. doi:10.1016/J.EURURO.2020.08.024

    8. Grossman HB et al. NEJM. 2003;349(9):859-866. doi:10.1056/NEJMOA022148/

    Disclosures

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags

    Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    Más Menos
    29 m
  • 01_14 Ampullary Carcinoma (Mini Discussion)
    Apr 11 2024

    1. Clinical presentation and work-up
    2. Intestinal and pancreatobiliary subtypes
    3. Role of perioperative therapy
    4. Considerations for metastatic disease

    Citations

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.

    1. Neoptolemos JP et al. JAMA. 2010;304(10):1073-1081. doi:10.1001/JAMA.2010.1275

    2. Smeenk HG et al.. Ann Surg. 2007;246(5):734-740. doi:10.1097/SLA.0B013E318156EEF3

    3. Chang DK , et al. J Clin Oncol. 2013;31(10):1348-1356. doi:10.1200/JCO.2012.46.8868

    4. Schueneman A et al. Br J Cancer. 2015;113(1):64-68. doi:10.1038/BJC.2015.172

    5. Chiorean EG et al. Journal of the National Comprehensive Cancer Network. 2023;21(7):753-782. doi:10.6004/JNCCN.2023.0034

    Disclosures

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags

    Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    Más Menos
    11 m
  • 04_04 Castrate Resistant Metastatic Prostate Cancer
    Feb 22 2024

    1. On continuation of ADT and ARAT switch
    2. Systemic therapy options after progression
    3. Improper mandated crossover
    4. PARP inhibitors in prostate cancer

    Citations

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.

    1. Freedland SJ et al. NEJM. 2023;389(16):1453-1465. doi:10.1056/NEJMOA2303974/

    2. de Bono J et al. NEJM. 2020;382(22):2091-2102. doi:10.1056/NEJMOA1911440/

    3. Haslam A, Prasad V. Annals of Oncology. 2018;29(5):1079. doi:10.1093/ANNONC/MDY116

    4. Parker C et al. NEJM. 2013;369(3):213-223. doi:10.1056/NEJMOA1213755/

    5. Khalaf DJ et al. Lancet Oncol. 2019;20(12):1730-1739. doi:10.1016/S1470-2045(19)30688-6

    6. Saad F et al.. J Natl Cancer Inst. 2004;96(11):879-882. doi:10.1093/JNCI/DJH141

    7. Sartor O et al. NEJM. 2021;385(12):1091-1103. doi:10.1056/NEJMOA2107322/

    8. de Wit R et al. NEJM. 2019;381(26):2506-2518. doi:10.1056/NEJMOA1911206/

    Disclosures

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags

    Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    Más Menos
    25 m
  • 04_03 Metastatic Castrate Sensitive Prostate Cancer
    Feb 4 2024

    1. The chemotherapy revolution in prostate cancer
    2. Role of ARATs in earlier disease states
    3. Triple therapy (chemotherapy, ADT, and ARAT)
    4. Considerations for frailer patients with indolent disease

    Citations

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.

    1. Hussain M et al.. J Clin Oncol. 2023;41(20):3595-3607. doi:10.1200/JCO.23.00041

    2. Smith MR et al. NEJM. 2022;386(12):1132-1142. doi:10.1056/NEJMOA2119115/

    3. Fizazi K et al. Lancet. 2022;399(10336):1695-1707. doi:10.1016/S0140-6736(22)00367-1

    4. Sweeney CJ et al. Lancet Oncol. 2023;24(4):323-334. doi:10.1016/S1470-2045(23)00063-3

    5. Wenzel M, et al. Prostate Cancer and Prostatic Diseases 2021 25:2. 2021;25(2):139-148. doi:10.1038/s41391-021-00395-4

    6. Gravis G et al. Lancet Oncol. 2013;14(2):149-158. doi:10.1016/S1470-2045(12)70560-0

    7. James ND et al. NEJM. 2017;377(4):338-351. doi:10.1056/NEJMOA1702900/SUPPL_FILE/

    8. Fizazi K, et al. Lancet Oncol. 2019;20(5):686-700. doi:10.1016/S1470-2045(19)30082-8

    9. James ND et al. Lancet. 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5

    10. Gravis G et al. Lancet Oncol. 2013;14(2):149-158. doi:10.1016/S1470-2045(12)70560-0

    11. Sweeney CJ et al. NEJM. 2015;373(8):737-746. doi:10.1056/NEJMOA1503747/SUPPL_FILE\

    12. James ND et al. The Lancet. 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5

    13. Fizazi K et al. NEJM. 2017;377(4):352-360. doi:10.1056/NEJMOA1704174

    14. Tannock et al. NEJM 2004;351(15):1502-1512. doi:10.1056/NEJMOA040720

    15. Petrylak DP et al.. NEJM. 2004;351(15):1513-1520. doi:10.1056/NEJMOA041318

    Disclosures

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags

    Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    Más Menos
    29 m
  • 04_02 Adjuvant Options for Prostate Cancer
    Jan 8 2024

    1. Physiology, efficacy and toxicities of androgen deprivation
    2. Evidence for adjuvant intervention after definitive surgery or radiation
    3. Role of abiraterone in high-risk localized prostate cancer
    4. Limited evidence to support definitive salvage approach

    Citations

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.


    1. Attard G et al. Lancet. 2022;399(10323):447-460. doi:10.1016/S0140-6736(21)02437-5

    2. Xie W et al. J Clin Oncol. 2017;35(27):3097-3104. doi:10.1200/JCO.2017.73.9987

    3. Bolla M et al.. NEJM. 2009;360(24):2516-2527. doi:10.1056/NEJMOA0810095/

    4. Kishan AU et al. Lancet Oncol. 2022;23(2):304-316. doi:10.1016/S1470-2045(21)00705-1

    5. Bolla M et al. Lancet. 2002;360(9327):103-108. doi:10.1016/S0140-6736(02)09408-4

    6. Bolla M et al. Lancet Oncol. 2010;11(11):1066-1073. doi:10.1016/S1470-2045(10)70223-0

    7. Bolla M et al. NEJM. 2009;360(24):2516-2527. doi:10.1056/NEJMOA0810095/

    8. Hanks GE et al. J Clin Oncol. 2003;21(21):3972-3978. doi:10.1200/JCO.2003.11.023

    9. Bolla M et al. Lancet. 2002;360(9327):103-108. doi:10.1016/S0140-6736(02)09408-4

    10. Huggins C, Hodges C V. CA Cancer J Clin. 1972;22(4):293-297. doi:10.3322/CANJCLIN.22.4.232

    11. Huggins C et al. Arch Surg. 1941;43(2):209-223. doi:10.1001/archsurg.1941.01210140043004

    12. Rosenthal SA et al. J Clin Oncol. 2019;37(14):1159-1168. doi:10.1200/JCO.18.02158

    Disclosures

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags

    Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    Más Menos
    29 m
  • 04_01 Fundamentals of Localized Prostate Cancer
    Dec 18 2023

    1. Background and presentation of prostate Cancer
    2. Evidence behind PSA screening and hallmarks of a screening test
    3. Staging and risk stratification of Localized Disease
    4. Management options and the ProtecT Trial

    Citations

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.

    1.Schroder F et al. NEJM. 2009; 360(13):1320-1328. doi: 10.1056/NEJMOA0810084/

    2. Andriole G el al. NEJM. 2009; 360(13):1310-1319. doi: 10.1056/NEJMOA0810696/

    3. Lane J et al. Lancet. 2014; 15(10):1109-1118. doi: 10.1016/S1470-2045(14)70361-4

    4. Hamdy F et al. NEJM. 2016; 375(15):1415-1424. doi: 10.1056/NEJMOA1606220

    5. Hamdy F et al. NEJM. 2023; 388(17):1547-1558. doi: 10.1056/NEJMOA2214122/

    6. Ilic D et al. BMJ. 2018; 362:k3519. doi:10.1136/BMJ.K3519

    7.Maurer T et al. Nat Rev Urol. 2016;13(4):226-235. doi: 10.1038/nrurol.2016.26. Epub 2016 Feb 23

    Disclosures

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags

    Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology




    Más Menos
    32 m